GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rallybio Corp (NAS:RLYB) » Definitions » ROIC %

Rallybio (Rallybio) ROIC % : -1,660.89% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Rallybio ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Rallybio's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -1,660.89%.

As of today (2024-05-10), Rallybio's WACC % is 10.44%. Rallybio's ROIC % is -1469.27% (calculated using TTM income statement data). Rallybio earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Rallybio ROIC % Historical Data

The historical data trend for Rallybio's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rallybio ROIC % Chart

Rallybio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-2,567.98 -3,938.91 -1,875.43 -1,345.04 -1,572.51

Rallybio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,892.43 -1,170.32 -1,478.19 -1,535.98 -1,660.89

Competitive Comparison of Rallybio's ROIC %

For the Biotechnology subindustry, Rallybio's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rallybio's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rallybio's ROIC % distribution charts can be found below:

* The bar in red indicates where Rallybio's ROIC % falls into.



Rallybio ROIC % Calculation

Rallybio's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-78.932 * ( 1 - 0% )/( (5.823 + 4.216)/ 2 )
=-78.932/5.0195
=-1,572.51 %

where

Rallybio's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-84.448 * ( 1 - 0% )/( (5.953 + 4.216)/ 2 )
=-84.448/5.0845
=-1,660.89 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rallybio  (NAS:RLYB) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Rallybio's WACC % is 10.44%. Rallybio's ROIC % is -1469.27% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Rallybio ROIC % Related Terms

Thank you for viewing the detailed overview of Rallybio's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rallybio (Rallybio) Business Description

Traded in Other Exchanges
N/A
Address
234 Church Street, Suite 1020, New Haven, CT, USA, 06510
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Executives
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jonathan I Lieber officer: See Remarks C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Wendy Chung director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Hui Liu director C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Christine A Nash director C/O RALLYBIO CORPORATION, 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510